



Director of Statistics
As a Director of Statistics, you will be accountable for the statistical activities and line management of statisticians within the company. Guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.
Read More...Upcoming Events
PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
PSI Journal Club: Survival Analysis
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
PSI VisSIG Webinar: Rapid Insights to Data
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
PSI One-Day Meeting: Non-proportional hazards and applications in immuno-oncology
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
Special Interest Groups
AIMS
The Application and Implementation of Methodologies in Statistics (AIMS)
Benefit-Risk
The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.
COVID-19
Data Science
Bridging Data Science knowledge and expertise across various groups and functions within the pharmaceutical industry to increase collaboration, awareness, knowledge sharing and enhance drug development. We’ll encourage the development of new statistical and machine learning methods and approaches as well as in novel applications of the well-established methods.
Data Transparency
Sharing experiences and challenges of external patient level data sharing with particular focus on data privacy and anonymization processes.
Decision Making
The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development.
Historical Data
What is the state of the art regarding approaches to incorporate historical data into the formal design and analysis of clinical trials, Which statistical methods should we use to make historical and current data comparable, What are the regulatory requirements necessary for the acceptance of historical data in drug approval?
HTA
The purpose of the Healthcare Technology Assessment SIG is to provide statisticians working in the Pharmaceutical Industry engaged in Health Technology Assessments, and others in related fields of research...
Neuroscience-Estimands
This SIG will connect the following two topics: general biostatistics Neuroscience community, and working groups on estimands & other topics in Neuroscience.
New Starters
A special interest group to facilitate networking amongst ‘new starters’ (statisticians and programmers) working in medical research - the pharmaceutical industry, Contract Research Organisations and Clinical Trial Units. The group will organise between one and three events per year to achieve this. Networking will be facilitated through three types of event – symposia, development and social.
Oncology-Estimands
The draft addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in August 2017 and introduced an estimand framework. In February 2018, Evgeny Degtyarev from Novartis and Kaspar Rufibach from Roche started an informal working group to discuss how to implement the draft addendum in oncological clinical trials.
Regulatory
The regulatory SIG co-ordinates regulatory activities across the European Pharmaceutical Statistical community and to engage with European Regulatory statisticians.
Subgroup Analysis
Subgroup analysis is routinely conducted in drug development, in various settings; one key aspect is the regulatory requirement to demonstrate consistency of treatment effect across a pre-defined set of subgroups (e.g., ICHE5, E9, E17).
Toxicology
To provide a forum to discuss the statistical issues involved in Regulatory and Investigative Toxicology.
Vaccines
Creating a professional platform for statisticians in the Pharmaceutical industry, Regulatory agencies and Public Health organizations working on the research and development of vaccines to understand how best to apply methodologies.
Visualisation
Effective visualisation of data should belong to the core skills of statisticians as it represents an essential tool in exploring data as well as explaining data.